Our Research & Discovery Platform
Regenerative Medical Solutions’ research and discovery platform is built on a proprietary human induced pluripotent stem cell (iPSC) platform designed to support drug discovery, beta cell toxicity testing, and regenerative medicine research. This scientific engine complements RMS’s work on its prospective diabetes cure and broader regenerative medicine initiatives.
By leveraging differentiated human iPSC-derived islet-like cells, RMS provides pharmaceutical companies, biotechnology firms, academic institutions, and government laboratories with scalable, high-quality cell-based testing systems. These tools enable earlier, more predictive evaluation of candidate therapies targeting insulin-secreting beta cells. RMS’s iPSC research platform supports both therapeutic innovation and drug discovery applications within a unified regenerative medicine framework.
This platform is guided by our experienced scientific and executive leadership, whose expertise in pancreatic islet biology and regenerative medicine is detailed on our About Regenerative Medical Solutions page and through our Leadership Team profiles.
Addressing Critical Gaps in Drug Discovery
Drug development remains a high-risk process. Many candidate therapies fail due to lack of efficacy or unforeseen toxicity, often discovered only after significant investment in late-stage trials. Traditional toxicity studies frequently rely on animal models, which may not accurately predict human cellular responses.
Human cell-based testing platforms offer a more predictive approach. RMS’s iPSC platform enables beta cell toxicity testing using insulin-secreting islet-like cells derived from adult human cells. By incorporating human iPSC-derived cells into screening workflows, drug developers can assess potential toxicity and functional impact earlier in the development process, particularly in applications involving beta cell toxicity testing and functional screening, helping reduce risk and improve translational accuracy.
Insights from this platform continue to strengthen RMS’s growing intellectual property portfolio and proprietary differentiation protocols.
The RMS iPSC Platform: Human Islet-Like Cells for Scalable Screening
RMS produces functional islet-like cells through its proprietary differentiation process, detailed further on our ILC Cell Generation page, and supported by its ProgenMix® media formulation. These iPSC-derived cells are generated from adult human tissues (such as blood or skin), reprogrammed into pluripotent stem cells, and directed into insulin-producing cell types.
Key platform capabilities include:
- Consistent batch-to-batch production under controlled laboratory conditions
- Availability in standard 12-, 24-, 96-, and 384-well plate formats
- Compatibility with automated screening systems
- Demonstrated survivability and durability during domestic and international shipment
RMS has successfully distributed its cell products throughout the United States and internationally, including Europe and Asia. This operational robustness supports integration into large-scale pharmaceutical screening workflows.
Compared to cadaver-derived human islet cells, which are limited in supply and subject to donor variability, RMS’s iPSC-derived islet-like cells provide a more abundant, reliable, and standardized alternative suitable for research and drug discovery applications.
RMS’s stem cell research tools provide pharmaceutical developers with scalable human beta cell models for testing. These capabilities build upon RMS’s foundation of peer-reviewed scientific publications and academic research.
Ethical and Non-Embryonic Stem Cell Technology
RMS’s cell products are derived exclusively from non-embryonic human induced pluripotent stem cells. Because iPSCs are generated from adult tissues rather than embryos, this approach avoids ethical concerns associated with embryonic stem cell use.
Feedback from industry stakeholders indicates that some organizations prefer or require non-embryonic stem cell sources. RMS’s iPSC platform aligns with these preferences while maintaining scientific rigor and scalability.
Market Context and Demand for Human Islet-Like Cells
Access to functional human islet cells remains limited. Cadaver-derived islets are costly and often available only intermittently due to donor supply constraints. Additionally, variability in donor health and harvesting conditions can result in inconsistent quality and performance.
In contrast, RMS’s cell products are produced under defined laboratory conditions with quality controls designed to promote consistency and reliability.
Historical distribution patterns from academic islet centers in the United States and Europe indicate sustained demand for human islet cells in research applications, with supply frequently constrained relative to need. These limitations have created ongoing challenges for researchers and pharmaceutical developers seeking reliable access to human beta cell models.
Given persistent supply constraints and the growing emphasis on human cell-based drug screening, the market for scalable, standardized islet-like cells represents a significant and underserved commercial opportunity within the broader drug discovery and toxicity testing landscape.
Strategic Partnerships and Global Distribution
RMS has established a partnership with MilliporeSigma to expand access to its cell products through established ecommerce channels and global sales networks. This collaboration enhances RMS’s market reach and facilitates integration into existing pharmaceutical and biotechnology procurement systems.
The ability to distribute internationally, combined with scalable manufacturing and standardized production processes, supports broader adoption of RMS’s iPSC-derived research tools across global markets.
RMS also offers specialized biotech consulting services to support organizations advancing stem cell and regenerative medicine initiatives.
Supporting RMS’s Broader Regenerative Medicine Strategy
RMS’s research and discovery platform is closely integrated with its therapeutic development efforts. Insights gained through drug discovery collaborations and cell-based testing applications help refine differentiation protocols, strengthen intellectual property, and enhance translational understanding of beta cell biology.
As a regenerative medicine platform company, RMS leverages its proprietary iPSC platform not only to advance stem cell therapy for diabetes, but also to deliver practical research tools that address current needs in drug development and toxicity testing.
By combining therapeutic development with commercially relevant research solutions, RMS continues to strengthen the scientific platform supporting its long-term goal of developing a safe and effective cure for diabetes.